Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinaseJohn T Sisko, Thomas J Tucker, Mark T Bilodeau, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPMark E Fraley, Robert M Garbaccio, Kenneth L Arrington, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel AntagonistsJames C Barrow, Kenneth E Rittle, Thomas S Reger, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2017
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokineticsScott E Wolkenberg, M Brad Nolt, Mark T Bilodeau, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2007
Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSPPaul J Coleman, John D Schreier, Christopher D Cox, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2006
3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6Mark E Fraley, Justin T Steen, Edward J Brnardic, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitorsEdward J Brnardic, Robert M Garbaccio, Mark E Fraley, et al.
Chemmedchem|December 31, 2013
Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaAnthony J Roecker, Swati P Mercer, John D Schreier, et al.
Pageof 12